-
Polgreen, LE, Savarirayan, R, Wilcox, WW, Harmatz, P, Phillips, J, Tofts, L, Ozono, K, Arundel, P, Irving, M, Bacino, CA, et al.
A randomized controlled trial of vosoritide in infants and toddlers with Achondroplasia.
Zeitschrift für Geburtshilfe und Neonatologie
227:
e165 -e166
2024
view publication
-
Savarirayan, R, Tofts, L, Irving, M, Wilcox, W, Bacino, C, Hoover-Fong, J, Font, RU, Harmatz, P, Rutsch, F, Carroll, R, et al.
P139: Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 4 years: Update from phase 3 extension study*.
Genetics in Medicine Open
2:
101036
2024
view publication
-
Savarirayan, R, Wilcox, W, Harmatz, P, Phillips, J, Polgreen, L, Tofts, L, Ozono, K, Arundel, P, Irving, M, Bacino, C, et al.
P131: Persistence of growth-promoting effects in infants and toddlers with achondroplasia: Results from a phase II extension study with vosoritide*.
Genetics in Medicine Open
2:
101028
2024
view publication
-
Hoover-Fong, J, Irving, M, Bacino, C, Charrow, J, Prada, C, Cormier-Daire, V, Polgreen, L, Harmatz, P, Ghani, S, Fisheleva, E, et al.
P144: Persistence of growth-promoting effects in children with achondroplasia up to 7 years: Update from phase 2 extension study with vosoritide*.
Genetics in Medicine Open
2:
101041
2024
view publication
-
Savarirayan, R, Tofts, L, Irving, M, Wilcox, W, Bacino, C, Hoover-Fong, J, Font, RU, Harmatz, P, Rutsch, F, Carroll, R, et al.
P141: Persistent growth-promoting effects of vosoritide in children with achondroplasia is accompanied by improvement in physical aspects of quality of life*.
Genetics in Medicine Open
2:
101038
2024
view publication